mavacamten mavacamten mavacamten, sold under the brand name camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy. mavacamtenclinical datatrade namescamzyosother namesmyk-461license data us dailymed: mavacamten pregnancycategory au: d routes ofadministrationby mouthdrug classcardiac myosin inhibitoratc codec01eb24 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only us: ℞-only identifiers iupac name 6-amino]-3-propan-2-yl-1h-pyrimidine-2,4-dione cas number1642288-47-8pubchem cid117761397drugbankdb14921uniiqx45b99r3jkeggd12265chemical and physical dataformulac15h19n3o2molar mass273.336 g·mol−13d model (jsmol)interactive image smiles cc(c)n1c(=o)nc(n(c)c2=cc=cc=c2)=cc1=o inchi inchi=1s/c15h19n3o2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16h,1-3h3,(h,17,20)/t11-/m0/s1key:rlclasqcapxvlm-nshdsacasa-n mavacamten is a cardiac myosin inhibitor. it was developed by myokardia, a subsidiary of bristol myers squibb. mavacamten was approved for medical use in the united states in april 2022. the us food and drug administration (fda) considers it to be a first-in-class medication. medical uses mavacamten is indicated for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. history mavacamten was granted orphan drug designation by the u.s. food and drug administration (fda). society and culture legal status on 26 april 2023, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product camzyos, intended for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (ohcm). the applicant for this medicinal product is bristol-myers squibb pharma eeig. names mavacamten is the international nonproprietary name (inn).